JOHN JOHNSON - 13 Aug 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Director
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 13 Aug 2025
Net transactions value: -$786,459
Form type: 4
Filing time: 15 Aug 2025, 16:57:39 UTC
Previous filing: 20 Jun 2025
Next filing: 10 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
JOHNSON JOHN	Director	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	15 Aug 2025	0001410781

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Sale	$786,459	-107,500	-11%	$7.32	833,483	13 Aug 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.